Bioventus Gestion
Gestion contrôle des critères 4/4
Le PDG Bioventus est Rob Claypoole, nommé en Jan2024, a un mandat de 2.5 ans. La rémunération annuelle totale est $ 4.30M, composée du salaire de 19.2% et des bonus 80.8%, y compris les actions et options de la société. détient directement 0.2% des actions de la société, d'une valeur de $ 1.97M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 5.4 ans.
Informations clés
Rob Claypoole
Directeur général
US$4.3m
Rémunération totale
| Pourcentage du salaire du PDG | 19.17% |
| Durée du mandat du directeur général | 2.5yrs |
| Propriété du PDG | 0.2% |
| Durée moyenne d'occupation des postes de direction | 3.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.4yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • Jul 07
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Summary Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 17
BVS: 2026 Sales Guidance Will Support A Higher Share Price
Analysts maintained their $16.00 price target on Bioventus, noting only minor adjustments to assumptions such as the discount rate, revenue growth outlook, profit margin, and future P/E, which were not significant enough to change their overall valuation view. What's in the News for Bioventus Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, indicating expected net sales in the range of $600 million to $610 million.
Mise à jour du récit • Jun 03
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.Mise à jour du récit • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).Article d’analyse • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...Mise à jour du récit • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.Mise à jour du récit • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.Mise à jour du récit • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.Mise à jour du récit • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.Mise à jour du récit • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
Mise à jour du récit • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.Mise à jour du récit • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.Mise à jour du récit • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.Mise à jour du récit • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.Mise à jour du récit • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).Mise à jour du récit • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.Article d’analyse • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Mise à jour du récit • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.Mise à jour du récit • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.Mise à jour du récit • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.Mise à jour du récit • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.Article d’analyse • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...Article d’analyse • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...Nouveau récit • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Article d’analyse • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking AlphaAnalyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 28 2026 | n/a | n/a | US$28m |
| Dec 31 2025 | US$4m | US$824k | US$23m |
| Sep 27 2025 | n/a | n/a | US$10m |
| Jun 28 2025 | n/a | n/a | US$2m |
| Mar 29 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$6m | US$780k | -US$36m |
Rémunération vs marché: La rémunération totale de Rob ($USD 4.30M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 3.53M ).
Rémunération et revenus: La rémunération de Rob a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Rob Claypoole (54 yo)
2.5yrs
Titularisation
US$4,299,108
Compensation
Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, U.S for Mlnlycke Healt...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.5yrs | US$4.30m | 0.20% $ 2.0m | |
| Senior VP & CFO | 4.3yrs | US$1.90m | 0.26% $ 2.6m | |
| Senior VP | 8.9yrs | US$1.41m | 0.23% $ 2.2m | |
| Senior Vice President of Operations | 2.8yrs | pas de données | pas de données | |
| Vice President of Investor Relations & Treasurer | no data | pas de données | pas de données | |
| Senior VP & Chief Compliance Officer | 5.9yrs | pas de données | 0.095% $ 932.1k | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | pas de données | pas de données | |
| Senior VP & GM of Surgical | 1.6yrs | pas de données | pas de données |
3.3yrs
Durée moyenne de l'emploi
60.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BVS est considérée comme expérimentée (ancienneté moyenne 3.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.5yrs | US$4.30m | 0.20% $ 2.0m | |
| Independent Director | 5.8yrs | US$275.00k | 0.22% $ 2.2m | |
| Independent Director | 3.5yrs | US$290.00k | 0.17% $ 1.6m | |
| Independent Director | 5.8yrs | US$215.00k | 0.17% $ 1.7m | |
| Independent Chairman of the Board | 5.8yrs | US$380.00k | 0.44% $ 4.3m | |
| Independent Director | 5.8yrs | US$277.50k | 0.17% $ 1.7m | |
| Independent Director | 5.8yrs | US$300.00k | 0.20% $ 2.0m | |
| Independent Director | 5yrs | US$290.00k | 0.16% $ 1.6m | |
| Independent Director | 5.8yrs | US$245.00k | 0.065% $ 638.9k | |
| Independent Director | 4.8yrs | US$282.50k | 0.16% $ 1.6m | |
| Independent Director | 4.5yrs | US$280.00k | 0.11% $ 1.1m | |
| Independent Director | less than a year | pas de données | pas de données |
5.4yrs
Durée moyenne de l'emploi
59.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BVS sont considérés comme expérimentés (ancienneté moyenne 5.4 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/08 23:03 |
| Cours de l'action en fin de journée | 2026/07/08 00:00 |
| Les revenus | 2026/03/28 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bioventus Inc. est couverte par 11 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |